WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million
WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties.